Could an antidepressant help curb meth use in people treated for opioid addiction?
NCT ID NCT06323837
First seen Jul 02, 2026 · Last updated Jul 02, 2026
Summary
This phase 2 trial tests whether mirtazapine, an antidepressant, can help adults who are already receiving medication for opioid use disorder to stop or reduce their methamphetamine use. Participants are randomly assigned to receive either mirtazapine or a placebo for 10 weeks, alongside their usual treatment. The study measures methamphetamine abstinence through urine tests and also tracks sleep improvements.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Mirtazapine
What this could lead to
If it works, mirtazapine could become a new treatment option to help people reduce or stop methamphetamine use while receiving medication for opioid use disorder.
What could go wrong
This is a small, early-phase trial with only 60 participants. The drug may not prove more effective than placebo, and results may not apply to broader populations.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METHAMPHETAMINE USE DISORDER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- reSET App for Stimulant Use in HIV Patients – NCT05958017
- Preventing Methamphetamine Use in Postpartum Wom NCT05128071
- Ketamine-Assisted Psychotherapy for Methamphetam NCT06538285
- PTSD and Addiction Therapy in Jails Trial NCT07490717
- Semaglutide for Methamphetamine Use Disorder – NCT07509112
- rTMS for Stimulant Use Disorder Trial (NCT07112105)
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Spokane Treatment Center
RECRUITINGSpokane, Washington, 99208, United States
Contact